| scholarly article | Q13442814 |
| P50 | author | Joel M Gelfand | Q60659843 |
| P2093 | author name string | Nehal N Mehta | |
| Hyon K Choi | |||
| Daniel B Shin | |||
| Junko Takeshita | |||
| Thorvardur Jon Love | |||
| Zelma C Chiesa Fuxench | |||
| Alexis Ogdie | |||
| Megan H Noe | |||
| Neilia Kay McGill | |||
| P2860 | cites work | Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study | Q21135505 |
| Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? | Q26744032 | ||
| Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study | Q33789578 | ||
| Risk of venous thromboembolism in patients with rheumatoid arthritis | Q33877737 | ||
| 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres | Q34046881 | ||
| Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. | Q34111458 | ||
| Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden | Q34236174 | ||
| Inflammatory bowel disease and thromboembolism | Q34326640 | ||
| A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases | Q34392922 | ||
| Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations | Q34712199 | ||
| Validity of The Health Improvement Network (THIN) for the study of psoriasis. | Q34721703 | ||
| Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. | Q35124825 | ||
| Psoriasis is associated with a greater risk of incident venous thromboembolism: the Iowa Women's Health Study | Q35869918 | ||
| Validation of the diagnosis of venous thromboembolism in general practice database studies | Q36055463 | ||
| Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? | Q36327186 | ||
| Purposeful selection of variables in logistic regression | Q37077675 | ||
| Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. | Q37648544 | ||
| Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. | Q37730557 | ||
| Pulmonary embolism and deep vein thrombosis | Q38001827 | ||
| Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis | Q38178528 | ||
| Psoriasis and risk of venous thromboembolism: a systematic review and meta-analysis. | Q38203053 | ||
| Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis | Q38254002 | ||
| Predicting the risk of recurrent venous thromboembolism (VTE). | Q38365637 | ||
| Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases | Q38429239 | ||
| Rheumatoid arthritis in UK primary care: incidence and prior morbidity | Q38452419 | ||
| Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis | Q38489191 | ||
| Thrombosis in Autoimmune Diseases: A Role for Immunosuppressive Treatments? | Q38856768 | ||
| Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study | Q39499768 | ||
| Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs | Q40091147 | ||
| Epidemiology of venous thromboembolism | Q41667853 | ||
| The Read clinical classification | Q43175398 | ||
| The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. | Q43488992 | ||
| Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study | Q44326255 | ||
| Use of Glucocorticoids and Risk of Venous Thromboembolism | Q56644956 | ||
| Risk of Myocardial Infarction in Patients With Psoriasis | Q60711909 | ||
| The relationship between inflammation and venous thrombosis. A systematic review of clinical studies | Q81094196 | ||
| Risk of venous thromboembolism with rheumatoid arthritis | Q83162699 | ||
| Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system | Q87109306 | ||
| Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization | Q87405670 | ||
| P433 | issue | 39 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| psoriatic arthritis | Q511097 | ||
| venous thromboembolism | Q9397786 | ||
| P304 | page(s) | 3608-3614 | |
| P577 | publication date | 2017-04-20 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study | |
| P478 | volume | 39 |
| Q54232038 | C-reactive protein and risk of venous thromboembolism: Results from a population-based case-crossover study. |
| Q64906378 | Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry. |
| Q99202044 | National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1 |
| Q92619532 | Oxidative Stress in Rheumatoid Arthritis: What the Future Might Hold regarding Novel Biomarkers and Add-On Therapies |
| Q89718029 | Progress in the research on venous thromboembolism |
| Q92983742 | RNA expression and risk of venous thromboembolism in lung cancer |
| Q50148198 | Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. |
| Q99556760 | Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population-based cohort study |
| Q64070213 | Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study |
| Q92544807 | The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors |
| Q54123341 | Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? |
| Q90623544 | Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme |
| Q90702746 | [Janus kinase inhibitors : State of the art in clinical use and future perspectives] |
Search more.